Modern approaches to the use of gonadotropin-releasing hormone agonists of assisted reproductive technologies

Perminova S.G.; Mityurina E.V.; Amyan T.S.

doi:https://doi.org/10.17116/repro201824275-82

References:

Kupka MS, Ferraretti AP, De Mouzon J, Erb K, D’hoogheT, Castilla JA, Calhaz-Jorge C, De Geyter C, Goossens V; European IVF-Monitoring Consortium, for the European Society of Human Reproduction and Embryology. Assisted reproductive technology in Europe, 2010: Results generated from European Registers by ESHRE. Human Reproduction. 2014;29(10):2099-2113. https://doi.org/10.1093/humrep/deu175
Filicori M, Cognigni GE, Cantelli B. Effect of luteinizing hormone activity on ovulation induction outcome. In: Endocrine basis of reproductive function. Filicori M, eds. 2000;353-363.
Fleming R. Induction of ovulation in polycystic ovarian disease. Progress in Clinical and Biological Research. 1986;225:401-412.
Neves-e-Castro M, Reis-Valle A. Response of plasma oestradiol-17-beta to synthetic FSH-LH/RH: a preliminary study. The Journal of Steroid Biochemistry and Molecular Biology. 1976;7(9):701-704.
Nazarenko TA. Stimulyatsiya funktsii yaichnikov. M.: MEDpress-inform; 2008. (In Russ.)
Siristatidis CS, Gibreel A, Basios G, Maheshwari A, Bhattacharya S. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database of Systematic Reviews. 2015;11:CD006919. https://doi.org/10.1002/14651858.cd006919
Feldberg D, Farhi J, Ashkenazi J, Dicker D, Shalev J, Ben-Rafael Z. Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels. Fertility and Sterility. 1994;62(2):343-346.
Loutradis D, Drakakis P, Vomvolaki E, Antsaklis A. Different ovarian stimulation protocols for women with diminished ovarian reserve. Journal of Assisted Reproduction and Genetics. 2007;24(12): 597-611.
Surrey E. Management of the poor responder: the role of GnRH agonists and antagonists. Journal of Assisted Reproduction and Genetics. 2007;24(12):613-619.
Albuquerque LE, Tso LO, Saconato H, Albuquerque MC, Macedo CR. Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database of Systematic Reviews. 2013;31;(1):CD002808. https://doi.org/10.1002/14651858.CD002808.pub3
Wang R, Lin S, Wang Y, Qian W, Zhou L. Comparisons of GnRH antagonist protocol versus GnRH agonist long protocol in patients with normal ovarian reserve: a systematic review and meta-analysis. PLoS One. 2017;24;12(4):e0175985. https://doi.org/10.1371/journal.pone.0175985
Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database of Systematic Reviews. 2006;3:CD001750. https://doi.org/10.1002/14651858.cd001750.pub2
Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews. 2016;4:CD001750. https://doi.org/10.1002/14651858.cd001750.pub4
Manno M, Cervi M, Zadro D, Fuggetta G, Adamo V, Tomei F. Different ART outcomes at increasing peak estradiol levels with long and antagonist protocols: retrospective insights from ten years experience. Journal of Assisted Reproduction and Genetics.2011;28(8): 693-698. https://doi.org/10.1007/s10815-011-9570-4
Meuleman C, Vandenabeele B, Fieuws S, Spiessens C, Timmerman D, D’Hooghe T. High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners. Fertility and Sterility. 2009;92(1):68-74. https://doi.org/10.1016/j.fertnstert.2008.04.056
Adamyan LV, Andreeva EN, Apolikhina IA, Bezhenar VF, Gevorkyan MA, Gus AI, Demidov VN, Kalinina EA, Levakov SA, Marchenko LA, Popov AA, Sonova MM, Khashukoyeva AZ, Chernukha GE, Yarotskaya EL. Endometriosis: diagnosis, treatment and rehabilitation. Federal clinical guidelines for managing patients. Russian Society of Obstetricians and Gynecologists. 2013. (In Russ.)
Salam HN, Garcia-Velasco JA, Dias S, Arici A, Abou-Setta AM. Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis (Review). Cochrane Database of Systematic Reviews. 2006;1:CD004635. https://doi.org/10.1002/14651858.cd004635.pub2
Rodriguez-Purata J, Coroleu B, Tur R, Carrasco B, Rodriguez I, Barri PN. Endometriosis and IVF: are agonists really better? Analysis of 1180 cycles with the propensity score matching. Gynecological Endocrinology. 2013;29(9):859-862. https://doi.org/10.3109/09513590.2013.808327
Nazarenko TA, Balakhontseva OS. The use of gonadotrophin-releasing hormone analogues in ART programs (clinical lecture). Problemy reproduktsii. 2015;21(3):72-74. (In Russ.)
Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J, Abou-Setta AM. Gonadtropin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews. 2011;5:CD001750. https://doi.org/10.1002/14651858.cd001750.pub2
Barkalina NV, Korneeva IE. a-GnRH in ART (a review). Problemy reproduktsii. 2010;4:54-59. (In Russ.)
Engmann L, Benadiva C, Humaidan P. GnRH agonist trigger for the induction of oocyte maturation in GnRH antagonist IVF cycles: a SWOT analysis. Reproductive BioMedicine Online. 2016;32: 274-285. https://doi.org/10.1016/j.rbmo.2015.12.007
Cerrillo M, Rodriguez S, Mayoral M, Pacheco A, Martinez-Salazar J, Garcia-Velasco JA. Differential regulation of VEGF after final oocyte maturation with GnRH agonist versus hCG: a rationale for OHSS reduction. Fertility and Sterility. 2009;91:1526-1528. https://doi.org/10.1016/j.fertnstert.2008.08.118
Cerrillo M, Pacheco A, Rodriguez S, Gomez R, Delgado F, Pellicer A, Garcia-Velasco JA. Effect of GnRH agonist and hCG treatment on VEGF, angiopoietin-2, and VE-cadherin: trying to explain the link to ovarian hyperstimulation syndrome. Fertility and Sterility. 2011;95:2517-2519. https://doi.org/10.1016/j.fertnstert.2010.12.054
Humaidan P, Kol S, Papanikolaou EG; Copenhagen GnRH Agonist Triggering Workshop Group. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Human Reproduction Update. 2011;17(4):510-524. https://doi.org/10.1093/humupd/dmr008
Di Luigi AJ, Engmann L, Schmidt DW, Maier DB, Nulsen JC, Benadiva CA. Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting. Fertility and Sterility. 2010;94:1111-1114. https://doi.org/10.1016/j.fertnstert.2009.10.034
Oktay K, Turkcuoglu I, Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reproductive BioMedicine Online. 2010;20:783-788. https://doi.org/10.1016/j.rbmo.2010.03.004
Reddy J, Turan V, Bedoschi G, Moy F, Oktay K. Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience. Journal of Assisted Reproduction and Genetics. 2014;31:927-932. https://doi.org/10.1007/s10815-014-0248-6
Castillo JC, Garcia-Velasco J, Humaidan P. Empty follicle syndrome after GnRHa triggering versus hCG triggering in COS. Journal of Assisted Reproduction and Genetics. 2012;29:249-253. https://doi.org/10.1007/s10815-011-9704-8
Griffin D, Benadiva C, Kummer N, Budinetz T, Nulsen J, Engmann L. Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders. Fertility and Sterility. 2012;97(6):1316-1320. https://doi.org/10.1016/j.fertnstert.2012.03.015
Bodri D, Guillen JJ, Galindo A, Mataro D, Pujol A, Coll O. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Fertility and Sterility. 2009;91:365-371. https://doi.org/10.1016/j.fertnstert.2007.11.049
Garcia-Velasco JA, Motta L, Lopez A, Mayoral M, Cerrillo M, Pacheco A. Low-dose human chorionic gonadotropin versus estradiol/progesterone luteal phase support in gonadotropin releasing hormone agonist-triggered assisted reproductive technique cycles: understanding a new approach. Fertility and Sterility.2010;94: 2820-2823. https://doi.org/10.1016/j.fertnstert.2010.06.035
Kuang Y, Chen Q, Hong Q, Lyu Q, Ai A, Fu Y, Shoham Z. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reproductive BioMedicine Online. 2014;29:684-691. https://doi.org/10.1016/j.rbmo.2014.08.009
Youssef MA, Van der Veen F, Al-Inany HG, Mochtar MH, Griesinger G, Nagi Mohesen M, Aboulfoutouh I, van Wely M. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database of Systematic Reviews. 2014;10:CD008046. https://doi.org/10.1002/14651858.cd008046.pub4
Kolibianakis EM, Schultze-Mosgau A, Schroer A, van Steirteghem A, Devroey P, Diedrich K, Griesinger G. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Human Reproduction. 2005; 20:2887-2892. https://doi.org/10.1093/humrep/dei150
Humaidan P. Agonist trigger: what is the best approach? Agonist trigger and low dose hCG. Fertility and Sterility. 2012;97:529-530. https://doi.org/10.1016/j.fertnstert.2011.11.016
Humaidan P, Engmann L, Benadiva C. Luteal phase supplementation after gonadotropin-releasing hormone agonist trigger in fresh embryo transfer: the American versus European approaches. Fertility and Sterility. 2015;103:879-885. https://doi.org/10.1016/j.fertnstert.2015.01.034
Imbar T, Kol S, Lossos F, Bdolah Y, Hurwitz A, Haimov-Kochman R. Reproductive outcome of fresh or frozenthawed embryo transfer is similar in high-risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte maturation and intensive luteal support. Human Reproduction. 2012;27:753-759. https://doi.org/10.1093/humrep/der463
Iliodromiti S, Lan VT, Tuong HM, Tuan PH, Humaidan P, Nelson SM. Impact of GnRH agonist triggering and intensive luteal steroid support on live-birth rates and ovarian hyperstimulation syndrome: a retrospective cohort study. Journal of Ovarian Research. 2013;6(1):93. https://doi.org/10.1186/1757-2215-6-93
Devroey P, Polyzos NP, Blockeel C. An OHSS-Free Clinic by segmentation of IVF treatment. Human Reproduction. 2011;26: 2593-2597. https://doi.org/10.1093/humrep/der251
Ghobara T, Gelbaya TA, Ayeleke RO. Cycle regimens for frozen-thawed mbryo transfer (Review). Cochrane Database of Systematic Reviews. 2017;7:CD003414. https://doi.org/10.1002/14651858.cd003414.pub3
Hill MJ, Miller KA, Frattarelli JL. A GnRH agonist and exogenous hormone stimulation protocol has a higher live-birth rate than a natural endogenous hormone protocol for frozen-thawed blastocyst-stage embryo transfer cycles: an analysis of 1391 cycles. Fertility and Sterility. 2010;93(2):416-422. https://doi.org/10.1016/j.fertnstert.2008.11.027
Park C, Choi MH, Yang KM, Song IO. Pregnancy rate in women with adenomyosis undergoing fresh or frozen embryo transfer cycles following gonadotropin-releasing hormone agonist treatment. Clinical and Experimental Reproductive Medicine. 2016;43(3):169-173. https://doi.org/10.5653/cerm.2016.43.3.169
Gelbaya TA, Nardo LG, Hunter HR, Fitgerald CT, Horne G, Pease EEH. Cryopreserved-thawed embryo transfer in natural or down-regulated hormonally controlled cycles: a retrospective study. Fertility and Sterility. 2006;85:603-609. https://doi.org/10.1016/j.fertnstert.2005.09.015
Nekoo E, Chamani M, Tehrani E, Rashidi B, Tanha F, Kalantari V. Artificial endometrial preparation for frozen-thawed embryo transfer with or without pretreatment with depot gonadotropin releasing hormone agonist in women with regular menses. Journal of Family and Reproductive Health. 2015;9(1):1-4.
Greco E, Litwicka K, Arrivi C, Varricchio M, Caragia M, Greco A, Minasi M, Fiorentino F. The endometrial preparation for frozen-thawed euploid blastocyst transfer: a prospective randomized trial comparing clinical results from natural modified cycle and exogenous hormone stimulation with GnRH agonist. Journal of Assisted Reproduction and Genetics. 2016;33(7):873-884. https://doi.org/10.1007/s10815-016-0736-y
Spandorfer SD, Fasouliotis SJ, Cimmino C, Shpizner M, Veeck L, Rosenwaks Z. Blastocyst frozen embryo transfer (FET): comparison of outcome with replacement in natural or programmed/medicated cycle. Fertility and Sterility. 2004;82:154. https://doi.org/10.1016/j.fertnstert.2004.07.393
Al-Shawaf T, Yang D, Al-Magid Y, Seaton A, Iketubosin F, Craft I. Infertility: ultrasonic monitoring during replacement of frozen/thawed embryos in natural and hormone replacement cycles. Human Reproduction. 1993;8:2068-2074. https://doi.org/10.1093/oxfordjournals.humrep.a137983
Prato LD, Borini A, Cattoli M, Bonu MA, Sciajno R, Flamigni C. Endometrialpreparation for frozen-thawed embryo transfer with or without pretreatment with gonadotropin-releasing hormone agonist. Fertility and Sterility. 2002;77:956-960. https://doi.org/10.1016/s0015-0282(02)02960-6
Simon A, Hurwitz A, Zetner BS, Bdolah Y, Laufer N. Transfer of frozenthawed embryos in artificially prepared cycles with and without prior gonadotropin-releasing hormone agonist suppression: a prospective randomized study. Human Reproduction. 1998;13(10): 2712-2717.
van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews. 2011;10:CD009154. https://doi.org/10.1002/14651858
Tesarik J. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Human Reproduction. 2006;21:2572-2579. https://doi.org/10.1093/humrep/del173
Tesarik J, Hazout A, Mendoza C. Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Human Reproduction. 2004;19:1176-1180. https://doi.org/10.1093/humrep/deh235
Dattaprasad B, Abha M. Evaluation of the impact of gonadotropin-releasing hormone agonist as an adjuvant in luteal-phase support on IVF outcome. Journal of Human Reproductive Sciences. 2012;5:279-284. https://doi.org/10.4103/0974-1208.106341
Qublan H, Amarin Z, Al-Qudah M, Diab F, Nawasreh M, Malkawi S, Balawneh M. Luteal phase support with GnRH-a improves implantation and pregnancy rates in IVF cycles with endometrium of Human Fertility. 2008;11(1):43-47. https://doi.org/10.1080/14647270701704768
Isikoglu M, Ozgur K, Oehninger S. Extension of GnRH agonist through the luteal phase to improve the outcome of intracytoplasmic sperm injection. Journal of Reproductive Medicine. 2007;52(7): 639-644. https://doi.org/10.1016/j.fertnstert.2008.07.1717
Aboulghar MA, Marie H, Amin YM, Aboulghar MM, Nasr A, Serour GI, Mansour RT. GnRH agonist plus vaginal progesterone for luteal phase support in ICSI cycles: a randomized study. Reproductive BioMedicine Online. 2015;30(1):52-56. https://doi.org/10.1016/j.rbmo.2014.09.017
Zafardoust S, Jeddi-Tehrani M, Akhondi MM, Sadeghi MR, Kamali K, Mokhtar S, Badehnoosh B, Arjmand-Teymouri F, Fatemi F, Mohammadzadeh A. Effect of administration of single dose GnRH agonist in luteal phase on outcome of ICSI-ET cycles in women with previous history of IVF/ICSI failure: a randomized controlled trial. Journal of Reproduction and Infertility. 2015;16(2):96-101.
Isik AZ, Caglar GS, Sozen E, Akarsu C, Tuncay G, Ozbicer T, Vicdan K. Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reproductive BioMedicine Online. 2009;19(4):472-477. https://doi.org/10.1016/j.rbmo.2009.04.001
Kung HF, Chen MJ, Guua HF, Chen YF, Yi YC, Yen-Ping Ho J, Chou MM. Luteal phase support with decapeptyl improves pregnancy outcomes in intracytoplasmic sperm injection with higher basal folliclestimulating hormone or lower mature oocytes. Journal of the Chinese Medical Association. 2014;77(10):524-530. https://doi.org/10.1016/j.jcma.2014.07.001
Yildiz GA. The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2014;182:66-70. https://doi.org/10.1016/j.ejogrb.2014.08.026
van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews. 2015;7:CD009154. https://doi.org/10.1002/14651858.cd009154.pub2
Gallyamova EM, Perminova SG, Mityurina EV, Strelchenko DA. Impact of luteal-phase support with a GnRH agonist on the outcomes of IVF programs. Akusherstvo i ginekologiya. 2015;7:48-55. (In Russ.)